NA-931

Product Description

NA-931, based on the mechanism of action of four receptor agonists—IGF-1, GLP-1, GIP, and Glucagon—and their roles to facilitate weight loss without many of the adverse events associated with current obesity drugs. NA-931 is in Phase 2B clinical trials. NA-931 not only significantly reduces body fat but also preserves muscle mass. Furthermore, NA-931 exhibits a notable reduction in adverse events commonly associated with existing treatments. In the quadruple mechanism of action of NA-931, Insulin-like Growth Factor 1 (IGF-1) plays a pivotal role in fuel metabolism and regulation of body composition. Additionally, IGF-1 in conjunction with GLP‐1, and GIP have been shown to be effective for weight loss in non-diabetic patients with obesity when given as adjunctive therapy to diet and exercise. IGF-1 also contributes to modulating glucagon secretion by inhibiting the ability of low glucose concentration to stimulate glucagon expression and secretion. (Sourced from: https://www.biomedind.com/NA-931.html)

Mechanisms of Action: GLP-1 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biomed Industries, Inc.
Company Location:
Company CEO:
Additional Commercial Interests: None